Houston, Texas 77090

  • Negative Breast Cancer


The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.

Study summary:

A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 (next generation oral SERD) in combination with palbociclib versus anastrozole in combination with palbociclib for the treatment of patients with ER-positive breast cancer. The goal of the study is to demonstrate superiority of AZD9833 over anastrozole in the context of combination with palbociclib in first line setting.


Inclusion criteria: - Pre-/peri-menopausal women or men can be enrolled if amenable to be treated with concomitant, approved LHRH agonists for the duration of the study treatment. - De novo Stage 4 disease, or recurrence from early stage disease after standard adjuvant endocrine therapy meeting either one of the following criteria: 1. Received at least 24 months of AI treatment as part of their adjuvant therapy and at least 12 months have elapsed since the patient's last dose of adjuvant AI therapy without disease progression on treatment 2. Received at least 24 months of tamoxifen treatment as part of their adjuvant endocrine therapy - Histologically or cytologically documented diagnosis of ER+, HER2-negative breast cancer based on local laboratory results. - Previously untreated with any systemic anti-cancer therapy for their locoregionally recurrent or metastatic ER+ disease. - Measurable disease as defined per RECIST v.1.1 OR at least one lytic or mixed (lytic + sclerotic) bone lesion that can be assessed by CT or MRI. - Eastern Cooperative Oncology Group performance status of 0 or 1. - Adequate organ and marrow function. - Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion criteria: - Previous neoadjuvant or adjuvant treatment with an AI treatment +/- CDK4/6 inhibitor with disease recurrence while on or within 12 months of completing treatment. - Previous treatment with AZD9833. - Participation in another clinical study with a study treatment or investigational medicinal device administered in the last 4 weeks prior to randomization or concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study. - Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term. - Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease. - Any clinically important and symptomatic heart disease . - Currently pregnant (confirmed with positive pregnancy test) or breast-feeding. - As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, renal transplant and active bleeding diseases) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol. - Any concurrent anti-cancer treatment. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.



Primary Contact:

AstraZeneca Clinical Study Information Center
Phone: 1-877-240-9479
Email: information.center@astrazeneca.com

Backup Contact:


Location Contact:

Houston, Texas 77090
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.